Session

A multidisciplinary forum: How can we improve management of hormone-sensitive prostate cancer?

Industry session by FERRING PHARMACEUTICALS

  • Location:
    Room Vienna, North Hall (Level 1)
  • Chair:
     A. Briganti, Milan (IT)
  • Aims and objectives of this session

    • A multidisciplinary panel of clinicians will share best practice around the current place of androgen deprivation therapy (ADT) in the treatment of hormone-sensitive prostate cancer across the different stages of the disease
     – To include treatment adjuvant to surgery and radiation
     – In combination with chemotherapy
    • Highlight the differences in mechanism of action and compare efficacy and safety profiles of different ADT agents
    • Discuss future directions in hormonal treatment of prostate cancer

Welcome and introduction
 A. Briganti, Milan (IT)
The role of (neo) adjuvant hormonal treatment with surgery for localised high-risk and locally-advanced prostate cancer
 A. Briganti, Milan (IT)
Combining radiation therapy and androgen deprivation for intermediate- and high-risk prostate cancer - A critical review
 H. Payne, London (GB)
Hormonal therapies are not all the same: Role of antagonists vs agonists
 A.S. Merseburger, Lübeck (DE)
ADT & cardiovascular risks: Current evidence and future research
 D.J. Rosario, Sheffield (GB)
Panel discussion on future treatment directions